Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Predicting breast cancer drug response using a multiple-layer cell line drug response network model

Fig. 5

Comparison of the predicted missing response values using ML-CDN2 and the existed response values for two types of inhibitors. a Comparison of predicted missing and available observed IC50 values for EGFR mutant and wild-type cell lines for which experimental IC50 values were missing from the GDSC dataset for EGFR inhibitors, including afatinib, cetuximab, erlotinib, gefitinib and lapatinib. b Comparison of predicted missing and available observed IC50 values for BRAF mutant and wildtype cell lines for which experimental IC50 values were missing in the GDSC dataset for three MEK inhibitors, including AZD6244, RDEA119 and PD-0325901

Back to article page